Leukotriene antagonists

A compound represented by the following structural formula (I):

• ##STR29## wherein q is 0, 1 or 2;
• R.sub.1 is (L).sub.a --CH.sub.2).sub.b --(T).sub.c --M
• a is 0 or 1;
• b is 3 to 14;
• c is 0 or 1;
• L and T are independently sulfur, oxygen, or CH.sub.2 with the proviso that L and T are not sulfur when q is 1 or 2;
• and
• M is C.sub.1-4 alkyl, ethynyl, trifluoromethyl, isopropenyl, thienyl, cyclohexyl or phenyl unsubstituted or monosubstituted with Br, Cl, CF.sub.3, C.sub.1-4 alkoxy, C.sub.1-4 alkyl, methylthio, or trifluoromethylthio;
• Y is (CHX).sub.n (CH.sub.2).sub.p --Z wherein
• R.sub.3 is OH, NH.sub.2, aryloxy, or C.sub.1-6 alkoxy;
• n is 0 or 1;
• p is 0 or 1;
• X is H, OH, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, or F;
• and
• Z is COR.sub.3, or tetrazolyl;
• R is ##STR30## R.sub.5 and R.sub.6 are independently hydrogen or C.sub.1-4 alkyl at any point when d is not O;
• d is 0 to 6;
• W is phenyl, unsubstituted or substituted with B, C, or D;
• or W is ##STR31## B is ##STR32## wherein R.sub.5 and R.sub.6 are independently hydrogen or C.sub.1-4 alkyl;
• p is 0 to 6;
• V is H, C1-4alkyl, COR.sub.3, SO.sub.3 H, SO.sub.2 H, SO.sub.2 NH.sub.2 HN.sub.2, COCH.sub.2 OH, CHOHCH.sub.2 OH, or tetrazolyl, with R.sub.3 as defined above;
• C and D are independently selected from H, OH, F, Cl, Br, CF.sub.3, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, methylthio, trifluoromethylthio, NO.sub.2, NH.sub.2, NHC.sub.1-4 alkyl, or C.sub.1-4 alkylCO-;
• or a pharmaceutically acceptable salt thereof.